Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Spiegel

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Kidney International|October 23, 2014
Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidismGeert J Behets, Goce Spasovski, Lulu R Sterling, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 6, 2010
A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3James Tumlin, Jesse Goldman, David M Spiegel, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|April 22, 2009
Coronary and aortic calcifications in patients new to dialysisDavid M Spiegel, Paolo Raggi, Ravindra Mehta, et al.
American Journal of Nephrology|December 20, 2015
Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing ReceptorDavid A Bushinsky, Geoffrey A Block, Kevin J Martin, et al.
BMC Nephrology|November 6, 2012
Outpatient red blood cell transfusion payments among patients on chronic dialysisMatthew Gitlin, J Andrew Lee, David M Spiegel, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 29, 2016
Effect of Patiromer on Urinary Ion Excretion in Healthy AdultsDavid A Bushinsky, David M Spiegel, Coleman Gross, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 17, 2020
The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiationNahid Tabibzadeh, Angelo Karaboyas, Bruce M Robinson, et al.
Journal of the American Society of Nephrology : JASN|July 24, 2012
Effects of phosphate binders in moderate CKDGeoffrey A Block, David C Wheeler, Martha S Persky, et al.
Seminars in Thrombosis and Hemostasis|November 1, 2012
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR)Charles L Bennett, David M Spiegel, Iain C Macdougall, et al.
JAMA|January 19, 2017
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical TrialsGeoffrey A Block, David A Bushinsky, John Cunningham, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Kidney International|October 23, 2014
Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidismGeert J Behets, Goce Spasovski, Lulu R Sterling, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 6, 2010
A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3James Tumlin, Jesse Goldman, David M Spiegel, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|April 22, 2009
Coronary and aortic calcifications in patients new to dialysisDavid M Spiegel, Paolo Raggi, Ravindra Mehta, et al.
American Journal of Nephrology|December 20, 2015
Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing ReceptorDavid A Bushinsky, Geoffrey A Block, Kevin J Martin, et al.
BMC Nephrology|November 6, 2012
Outpatient red blood cell transfusion payments among patients on chronic dialysisMatthew Gitlin, J Andrew Lee, David M Spiegel, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 29, 2016
Effect of Patiromer on Urinary Ion Excretion in Healthy AdultsDavid A Bushinsky, David M Spiegel, Coleman Gross, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 17, 2020
The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiationNahid Tabibzadeh, Angelo Karaboyas, Bruce M Robinson, et al.
Journal of the American Society of Nephrology : JASN|July 24, 2012
Effects of phosphate binders in moderate CKDGeoffrey A Block, David C Wheeler, Martha S Persky, et al.
Seminars in Thrombosis and Hemostasis|November 1, 2012
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR)Charles L Bennett, David M Spiegel, Iain C Macdougall, et al.
JAMA|January 19, 2017
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical TrialsGeoffrey A Block, David A Bushinsky, John Cunningham, et al.
Pageof 4